Abstract:The final, formatted version of the article will be published soon. You have multiple emails registered with Frontiers: Please enter your email address: If you already have an account, please login You don't have a Frontiers account ? You can register here Tuberculosis (TB) has once again become the world's leading cause of death from a single infectious agent following three years of COVID19 pandemic [1]. Accounting for 1.25 million deaths, TB remains the leading cause of death among people living with human immunodeficiency virus (HIV) (PLWH) [1], and was responsible for approximately twice as many deaths as HIV/ acquired immunodeficiency syndrome (AIDS) alone [2]. The immune responses to monoinfection with the causative agent, Mycobacterium tuberculosis (Mtb), are distinct from those observed in individuals infected with HIV or in those who are coinfected with both pathogens [3,4]. Pulmonary TB represents the most common manifestation of the active disease, characterized by the presence of classical lung caseous/necrotic granuloma lesions, accompanied by exudation. The disease typically progresses after two years of a latent TB infection, an asymptomatic immune activated phase following the initial primary infection [1,5].The immune cells involved in the responses to Mtb infection include innate myeloid cells, such as macrophages and neutrophils, and adaptive lymphocytes including T and B cells. If the equilibrium between innate and adaptive immune cells, which is essential for maintaining an appropriate proinflammatory/anti-inflammatory cytokine milieu, is disrupted, Mtb may disseminate from lungs to other organs, leading to the development of extrapulmonary TB. An appropriate adaptive response is necessary to facilitate the homing of effector T-lymphocytes, which is essential for the full organization and sustainability of the granuloma. This means that mycobacteria-containing macrophages are situated at the center, encircled by a rim of newly arrived lymphocytes that form a solid granuloma and exhibit a highly organized framework with high vascularization [6]. A failure to maintain this dynamic will result in structural disruption, thereby facilitating the migration of infected macrophages to other organs [7].It has long been established that functional impairments in both the innate and adaptive immune responses in PLWH contribute to an increased risk of TB disease in this population [8]. As a consequence of the immunodeficiency status generated by low CD4 + T-cell counts, this population is also more prone to the development of independent or concurrent extrapulmonary TB. Consequently, the pathophysiology of Mtb infection differs in HIV-positive individuals, and even more so in those who have progressed to severe AIDS phase. The mechanisms by which alterations in Mtb-specific T-cell responses may impede the early clearance of Mtb or sustained control of LTBI in PLWH remain poorly understood. PLWH appear to an altered cytokine profile in response to Mtb, which includes impairments in type I helper T-cell responses (Th1), a reduction in the activity of Th17 cells and regulatory T-cells, and an increase in immunosuppressive cytokines [8,9]. Furthermore, the incidence of smear-negative and subclinical TB is also higher among co-infected patients. This results in a reduction of the sensitivity of screening tests based on sputum examination.The identification of immune-related complexes or molecules that can be defined as diagnostic markers for Mtb in PLWH may facilitate the development of new diagnostic tools and the exploration of new therapeutic approaches. In comparison to monoinfections with either HIV or Mtb, during coinfection the immune cells subsets and functions in the peripheral blood, as well as their redistribution in local lesions, may undergo dramatic alterations. Additionally, deviations in the metabolism and the divergence of the ubiquitin machinery may also be observed. Altogether, the aforementioned factors represent the focus of this research topic.In this issue, an original research article by Yandrapally et al. (https://doi.org/10.3389/fimmu.2023.1276817) shows that the Mtb-secreted transcription regulator EspR contributes to a syndemic interaction during coinfection with HIV. It is hypothesized that binding to the putative cognate motif on the promoter region of the host IL-4 gene, leads to IL-4 gene expression, causing high IL-4 titers that induce a Th2-type microenvironment. Consequently, this results in a shift towards a Th2-type response, which facilitates macrophage polarization to a M2 anti-inflammatory and metabolic status that favours Mtb persistence. Chronic infection by HIV tends to induce a shift in the viral population from the R5 to the X4 phenotype, which is accompanied by an increasing in the expression of the CXCR4 receptor. This suggests that the mycobacteria-induced selection of X4 -Abstract Truncated-

Type I Interferon confers susceptibility to Mycobacterium tuberculosis infection within granulomas of SIV co-infected non-human primates

Pre-existing Simian Immunodeficiency Virus Infection Increases Expression of T Cell Markers Associated with Activation during Early Mycobacterium tuberculosis Coinfection and Impairs TNF Responses in Granulomas

SIV Infection Facilitates Mycobacterium Tuberculosis Infection of Rhesus Macaques

Type 1 interferon expression and signaling occur in distinct regions in granulomas during Mycobacterium tuberculosis infection

The role of IL-10 during early M. tuberculosis infection in a non-human primate model

Concurrent TB and HIV therapies effectively control clinical reactivation of TB during co-infection but fail to eliminate chronic immune activation

Role of Type I Interferons during Mycobacterium tuberculosis and HIV Infections

Editorial: Immune responses to MTB infection in people living with HIV

Lipid Peroxidation and Type I Interferon Coupling Fuels Pathogenic Macrophage Activation Causing Tuberculosis Susceptibility

Transiently boosting Vγ9+Vδ2+ γδ T cells early in Mtb coinfection of SIV-infected juvenile macaques does not improve Mtb host resistance.

Type I interferon responses contribute to immune protection against mycobacterial infection

Type I IFN signaling mediates NET release to promote Mycobacterium tuberculosis replication and granuloma caseation

Type I Interferon Responses by HIV-1 Infection: Association with Disease Progression and Control

Inhibition of Type I Interferon Signaling Abrogates Early Mycobacterium Bovis Infection

Deciphering lung granulomas in HIV & TB co-infection: unveiling macrophages aggregation with IL6R/STAT3 activation

Contrasting Inflammatory Signatures in Peripheral Blood and Bronchoalveolar Cells Reveal Compartment-Specific Effects of HIV Infection

HIV-1 but not SIVmac239 induces higher interferon-α antiviral state in chronic infected northern pig-tailed macaques (Macaca leonina)

Interleukin-1 receptor antagonist mediates type I interferon-driven susceptibility to Mycobacterium tuberculosis

Mycobacterium tuberculosis inhibits autocrine type I interferon signaling to increase intracellular survival

A protective role for type I interferon signaling following infection with Mycobacterium tuberculosis carrying the rifampicin drug resistance-conferring RpoB mutation H445Y

Mtb/HIV co-infection immune microenvironment subpopulations heterogeneity